Coordinating new HIV prevention methods worldwide
HIV Prevention Trials Network Leadership and Operations Center
This program tests new HIV prevention tools—like long-acting medicines, combined products that also prevent pregnancy or STIs, and antibody treatments—for people at higher risk of HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Family Health International NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11237571 on NIH RePORTER |
What this research studies
From your point of view, this program runs and organizes clinical work that tries to bring new ways to prevent HIV to the real world. It focuses on long-acting antiretroviral options for PrEP, multipurpose products that can prevent HIV and pregnancy or STIs, and antibody-based approaches, and it works with many communities at risk. The network designs trials, coordinates sites, manages safety and data, and partners with other research groups to try combined prevention approaches. If you are in a community the network serves, you might be able to join a study or contribute samples to help develop better prevention options.
Who could benefit from this research
Good fit: Ideal participants are people at higher risk for HIV such as sexually active young adults, men who have sex with men, transgender women, female sex workers, people who inject drugs, and women in sub-Saharan Africa.
Not a fit: People who are not at risk for HIV or those already living with untreated HIV seeking treatment rather than prevention are unlikely to benefit from these prevention-focused activities.
Why it matters
Potential benefit: If successful, this work could expand practical prevention choices—like long-acting PrEP, products that prevent HIV plus pregnancy or STIs, or antibody-based protection—reducing new HIV infections.
How similar studies have performed: Previous trials, including HPTN and other networks, have shown strong results for long-acting PrEP (e.g., cabotegravir) and ongoing work on multipurpose products and broadly neutralizing antibodies shows promise but remains more experimental.
Where this research is happening
Durham, United States
- Family Health International — Durham, United States (Active)
Researchers
- Principal investigator: Landovitz, Raphael J — Family Health International
- Study coordinator: Landovitz, Raphael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.